IDEX Corporation Q1 2026 Earnings Call Summary

Strategic Performance Drivers

• Performance was driven by a strategic pivot toward durable, high-growth markets including semiconductor, data center, and space and defense, which fueled 10% organic order growth.

• The Health & Science Technologies (HST) segment outperformed expectations due to secular demand for complex components that manage data, energy, and fluids in mission-critical environments.

• Management is increasingly utilizing 80/20 as a growth tool, deliberately segmenting markets to reallocate capital and talent toward the highest-value opportunities with winning customers.

• Fluid & Metering Technologies (FMT) saw strength in municipal water and mining, though results were partially offset by global softness in chemical end markets.

• The company is achieving a ‘flywheel effect’ where strengthening advantaged platforms allows for further portfolio rationalization, driving higher growth and stronger margins over time.

• Operational execution and productivity gains successfully offset negative mix and volume deleverage in the FMT and FSDP segments during the quarter.

Outlook and Strategic Assumptions

• Full-year 2026 organic growth guidance was raised to 3-4%, assuming high single-digit growth in HST and flattish performance in FMT and FSDP.

• The strong backlog build in HST provides enhanced visibility into late 2026 and 2027, particularly for long-cycle space and defense programs.

• Management maintains a cautious outlook for general industrial markets, modeling them as flattish due to ongoing geopolitical uncertainty and mixed signals from short-cycle diagnostic businesses.

• Capital allocation will remain balanced, with a commitment to $76 million in quarterly share repurchases throughout 2026. alongside active pursuit of bolt-on M&A.

• Free cash flow conversion is expected to be at least 100% for the full year, despite higher working capital requirements to support accelerated growth.

Operational Context and Risks

• Recent acquisitions like Muon, Micro-LAM, and Mott are currently dilutive to segment margins, but management expects 80/20 actions to drive them toward the segment average.

• The repeal of IEEPA tariffs and implementation of new administration tariffs are expected to be net-neutral to financial results.

• Life sciences remains a headwind due to inventory guarding by customers and funding pressures in academic and NIH-related markets.

• Gross margin declined 40 basis points year-over-year, primarily reflecting unfavorable product mix that offset productivity and volume gains.

Q&A Session Highlights

Path to returning HST margins to historical 30% levels

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.